Avisa Diagnostics Inc. (FOGCF)
Avisa Diagnostics Inc. operates in the Medical - Pharmaceuticals industry of the Healthcare sector, headquartered in Santa Fe, NM, US. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $97,176. On trailing twelve-month figures it carries a trailing P/E of -0.00, a net margin of -257.6%. Its beta of 1.28 implies it has historically moved more than the broad market.
Avisa Diagnostics Inc. is a medical device company currently in its clinical development phase. The company is advancing the Avisa BreathTest, an innovative drug-device biomarker platform. This technology enables the exceptionally rapid identification and quantitative monitoring of virulent bacterial pathogens, activated when patients inhale or ingest its proprietary diagnostic compounds. Avisa Diagnostics has successfully established clinical proof-of-concept through trials in cystic fibrosis, tuberculosis, and community-acquired pneumonia. Currently, the firm is concentrating its efforts on pivotal trials addressing Post-COVID-19 bronchiectasis and ventilator-associated pneumonia. Avisa Diagnostics Inc. is headquartered in Santa Fe, New Mexico.
Avisa Diagnostics Inc. is most often compared with the following Healthcare names: